Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

multibacillary leprosy - Clinical Profile, Genes & Research | Kisho | Kisho

Rare Disease

multibacillary leprosy

MONDO:0041751

Also known as:lepromatous leprosy

Find Clinical TrialsTrials

Overview

A lepromatous form of leprosy that is characterized by numerous infiltrated skin lesions displaying high bacillary loads, impaired peripheral nerves, possible involvement of internal organs, and a Th2-mediated immune response.

TreatmentsNo approved treatments · 1 in pipeline

Clinical Trials3 registered · 2 recruiting

Diagnosis

Biomarker and diagnostic research for multibacillary leprosy has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

No approved treatments are currently available for multibacillary leprosy. An additional 1 compound holds orphan drug designation.

Orphan Drug Designations

While no drugs are FDA-approved specifically for multibacillary leprosy, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.

The following drugs have received orphan drug designation from the FDA for multibacillary leprosy. Orphan designation reflects regulatory interest and does not indicate approval for treatment.

Brand Name	Generic Name	Sponsor

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

3 clinical trials registered, 2 recruiting. Interventions under study include other interventions and drug therapy. Pipeline includes 1 PHASE2, 1 NA. Research is primarily sponsored by academic and government institutions.

153 publications have been identified in PubMed for multibacillary leprosy. Kisho has analyzed 117 by research type. Research spans Case Report / Case Series (48%), Epidemiology / Natural History (16%), and Diagnostic / Biomarker (11%).

Research Type	Count	% of Total
Patient case studies	56

Data assembled from 4 of 12 sources · Last updated Sep 18, 2026, 4:24 AM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

Questions for Your Care Team

→Are any of the 3 active clinical trials a good fit for my situation?
→What is the current development status of heat killed mycobacterium w immunomodulator, and when might it become available?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

multibacillary leprosy

Overview

Diagnosis

Treatment

Orphan Drug Designations

Research Landscape

Medical References

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Clinical Trials

Recent Publications